Tofacitinib for Refractory Non-Infectious Ocular Inflammation: A Retrospective Observational Study.
Tofacitinib was associated with a significant reduction in ocular flares and improvement in visual outcomes in patients with refractory non-infectious ocular inflammation, suggesting that JAK inhibition may represent an effective and economically viable therapeutic option for selected patients with difficult-to-treat o...